918879-58-0

Basic information

• Product Name: H2ATSM/A
• CAS NO: 918879-58-0
• Molecular Formula: C₇H₁₅N₇S₂
• Molecular Weight: 261.37
• Mol File: 918879-58-0.mol

Chemical Properties

• CAS DataBase Reference: H2ATSM/A(CAS DataBase Reference)
• NIST Chemistry Reference: H2ATSM/A(918879-58-0)
• EPA Substance Registry System: H2ATSM/A(918879-58-0)

Safety Data

• Hazardous Substances Data: 918879-58-0(Hazardous Substances Data)

Usage

Uses

Used in Medical Imaging:
H2ATSM/A is used as a chelating agent for medical imaging techniques such as positron emission tomography (PET), where it binds to metal ions to improve the visualization of certain biological processes or conditions.
Used in Cancer Treatment:
H2ATSM/A is used as a targeted cancer therapy agent for selectively targeting and killing cancer cells by exploiting the metabolic differences between normal and cancerous cells, potentially improving the accuracy of cancer treatment and patient outcomes.
Used in Pharmaceutical Research:
H2ATSM/A is used as a subject of research for understanding its potential applications in medicine, including its mechanism of action, efficacy, and any potential side effects, to further develop its use in medical imaging and cancer treatment.

Upstream product

• 126971-40-2 diacetyl-2-(4-N-methyl-3-thiosemicarbazone) 
• 2231-57-4 Thiocarbohydrazide 

Downstream Products

• 1208998-90-6 C₁₃H₂₀N₁₀O₃S₂ 
• 1208998-91-7 C₁₀H₁₉N₇OS₂ 
• 1208998-89-3 C₁₃H₂₀N₁₀O₃S₂ 
• 1239597-25-1 diacetyl-2-(4-N-methyl-3-thiosemicarbazone)-3-(4-N-amino-(4-fluorobenzylamide)-3-thiosemicarbazone) 

Relevant articles and documents

Comparison of BTSE-RGD with DOTA-RGD as a potential imaging agent for tumors

RGD and its analogues are very important compounds and can be used as potential tumor-targeting agents. Bisthiosemicarbazone-conjugated RGD (BTSE-RGD) and DOTA-RGD were prepared using a chemical strategy based on peptide synthesis and chemoselective ligations. BTSE-RGD comprises two domains, the first a tumour selective domain and the other a chelating vehicle, for conjugation of radioisotopes. Both compounds were synthesized and labelled with 99mTc and radiochemically analysed by HPLC. The stability of the radioconjugate in the presence of human serum was checked at 37°C up to 8 h. Labelling yield of 96.8 ± 0.32% was obtained, which corresponds to a specific activity in the range of 36-89 MBq μmol-1 for BTSE-RGD. The BTSE-RGD conjugate was examined in vitro for its ability to bind with the αvβ3 receptor. The functionalized BTSE-RGD displayed a binding affinity toward αvβ3 integrin (31.9 ± 6.8 nM) many-fold better than DOTA-RGD. 99mTc-BTSE-RGD showed a slower distribution half-life (T1/2α) and elimination half-life (T1/2β) of 65 ± 0.001 min and 21 h 15 min ± 0.001 min, respectively, in comparison to 99mTc-DOTA-RGD, with T1/2α of 18 ± 0.001 min and T1/2β of 9 h 10 min ± 0.005 min. Biodistribution study showed better tumor-to-muscle ratio for BTSE-RGD, which reaches maximum around 3.5 (% ID) in 2 h, while for DOTA-RGD the maximum was 13.60 at 24 h.

Biotin Decorated Gold Nanoparticles for Targeted Delivery of a Smart-Linked Anticancer Active Copper Complex: In Vitro and in Vivo Studies

The synthesis and anticancer activity of a copper(II) diacetyl-bis(N4-methylthiosemicarbazone) complex and its nanoconjugates are reported. The copper(II) complex is connected to a carboxylic acid group through a cleavable disulfide link to enable smart delivery. The copper complex is tethered to highly water-soluble 20 nm gold nanoparticles (AuNPs), stabilized by amine terminated lipoic acid-polyethylene glycol (PEG). The gold nanoparticle carrier was further decorated with biotin to achieve targeted action. The copper complex and the conjugates with and without biotin, were tested against HeLa and HaCaT cells. They show very good anticancer activity against HeLa cells, a cell line derived from cervical cancer and are less active against HaCaT cells. Slow and sustained release of the complex from conjugates is demonstrated through cleavage of disulfide linker in the presence of glutathione (GSH), a reducing agent intrinsically present in high concentrations within cancer cells. Biotin appended conjugates do not show greater activity than conjugates without biotin against HeLa cells. This is consistent with drug uptake studies, which suggests similar uptake profiles for both conjugates in vitro. However, in vivo studies using a HeLa cell xenograft tumor model shows 3.8-fold reduction in tumor volume for the biotin conjugated nanoparticle compared to the control whereas the conjugate without biotin shows only 2.3-fold reduction in the tumor volume suggesting significant targeting.